Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 12, 2025Deleted JournalOpen Access

An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSithabiso D. MasukuCNCornelius NatteyLCLindi M. Coetzee

Discussion

Loading...

Member takes

Overview

Markov modeling shows improved treatment success and cost reductions for BPaL in multidrug-resistant TB patients in South Africa and the Philippines.

Key Points

  • BPaL-based regimens improve treatment success by 22%, enhancing patient adherence to full treatment.
  • Over 5 years, BPaL regimens reduce total costs by 20%-25% in South Africa and 9%-11% in the Philippines.
  • Initial budget increases for BPaL are outweighed by improvements in treatment success and long-term health outcomes.
  • Implementation in both countries supports a strong rationale for the rollout of BPaL regimens in combating multidrug-resistant TB.

Cite This Study

Masuku et al. (2025) studied this question.

synapsesocial.com/papers/68d41dae713b0b5dfea67318https://doi.org/10.5588/ijtldopen.25.0294
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pakistan’s path forward in DR-TB management: insights from global implementation of BPaL/BPaLM regimen2025
  2. 2Pretomanid: The life-saving drug to combat Pakistan’s TB crisis2025
  3. 3Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study2026
  4. 4Treatment Outcome of Bedaquiline-Based Oral Regimens for Drug-Resistant Tuberculosis in a High-Burden Setting.2025
  5. 5Cost-effectiveness of Targeted Next Generation Sequencing for TB drug-resistance testing as an alternative to the standard of care in South Africa2025